Concordance of confirmatory prostate biopsy in active surveillance with national guidelines: An analysis from the multi-institutional PURC cohort

Ruchika Talwar, Brian Friel, Sameer Mittal, Leilei Xia, Claudette Fonshell, John Danella, Bruce Jacobs, Thomas Lanchoney, Jay Raman, Jeffrey Tomaszewski, Edouard Trabulsi, Adam Reese, Eric Singer, Serge Ginzburg, Marc Smaldone, Robert Uzzo, Phillip Mucksavage, Thomas J. Guzzo, Daniel J. Lee

Research output: Contribution to journalArticle

Abstract

Purpose: National Comprehensive Cancer Network (NCCN) guidelines recommend confirmatory biopsy within 12 months of active surveillance (AS) enrollment. With <10 cores on initial biopsy, re-biopsy should occur within 6 months. Our objective was to determine if patients on AS within practices in the Pennsylvania Urologic Regional Collaborative (PURC) receive guideline concordant confirmatory biopsies. Materials and Methods: Within PURC, a prospective collaborative of diverse urology practices in Pennsylvania and New Jersey, we identified men enrolled in AS after first biopsy, analyzing time to re-biopsy and factors associated with various intervals of re-biopsy. Results: In total, 1,047 patients were enrolled in AS for a minimum of 12 months after initial biopsy. Four hundred seventy-seven (45%) underwent second biopsy at 1 of the 9 PURC practices. The number of patients undergoing re-biopsy within 6 months, 6 to 12 months, 12 to 18 months, and >18 months was 71 (14%), 218 (45.7%), 134 (28%), and 54 (11%), respectively. Sixty percent underwent confirmatory biopsy within 12 months. On multivariate analysis, re-biopsy interval was associated with number of positive cores, perineural invasion, and practice ID (all P < 0.05). Adjusted multivariable regression did not identify factors predictive of re-biopsy interval. Conclusion: Of patients who underwent confirmatory biopsy at PURC practices, 60.5% were within 12 months per NCCN guidelines. This suggests area for improvement in guideline adherence after enrollment in AS. All practices that offer AS should periodically perform similar analyses to monitor their performance. In an era of value-based care, adherence to guideline based active surveillance practices may eventually comprise national quality metrics affecting provider reimbursement.

Original languageEnglish (US)
JournalUrologic Oncology: Seminars and Original Investigations
DOIs
StateAccepted/In press - 2020

All Science Journal Classification (ASJC) codes

  • Oncology
  • Urology

Fingerprint Dive into the research topics of 'Concordance of confirmatory prostate biopsy in active surveillance with national guidelines: An analysis from the multi-institutional PURC cohort'. Together they form a unique fingerprint.

  • Cite this

    Talwar, R., Friel, B., Mittal, S., Xia, L., Fonshell, C., Danella, J., Jacobs, B., Lanchoney, T., Raman, J., Tomaszewski, J., Trabulsi, E., Reese, A., Singer, E., Ginzburg, S., Smaldone, M., Uzzo, R., Mucksavage, P., Guzzo, T. J., & Lee, D. J. (Accepted/In press). Concordance of confirmatory prostate biopsy in active surveillance with national guidelines: An analysis from the multi-institutional PURC cohort. Urologic Oncology: Seminars and Original Investigations. https://doi.org/10.1016/j.urolonc.2020.07.008